Did you know?

Real time Arcus Biosciences (RCUS) stock price quote, stock graph, news & analysis. HAYWARD, Calif., November 27, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented p14.06. +0.19. +1.37%. Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Thank you and welcome to the …HAYWARD, Calif., October 17, 2023--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ...... RCUS(RCUS)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与RCUS(RCUS) ... RCUS NYSE:RCUS Arcus Biosciences, I. 添加自选 在APP中查看.HAYWARD, Calif., August 07, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...Nov 8, 2023 · Arcus Biosciences Inc (NYSE: RCUS)’s stock price has plunge by 5.65relation to previous closing price of 15.57. Nevertheless, the company has seen a 4.71% surge in its stock price over the last five trading sessions. Seeking Alpha reported 2023-08-29 that Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an ... Arcus Biosciences, Inc. (NYSE:RCUS) is the most popular stock in this table. On the other hand Washington Trust Bancorp (NASDAQ: WASH ) is the least popular one with only 7 bullish hedge fund ...HAYWARD, Calif., July 11, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...Arcus Biosciences, Inc. (RCUS) NYSE - NYSE Delayed Price. Currency in USD Follow 2W 10W 9M 16.07 +1.01 (+6.71%) At close: 04:00PM ESTArcus Biosciences, Inc. (NYSE:RCUS) reports financial results for Q3 2023 and provides pipeline update. Domvanalimab shows promising results in Phase 2 EDGE-Gastric study for upper GI cancers. AB521 exhibits consistent results in cancer patients. Arcus expects to fund operations into 2026 with $950 million in cash and equivalents.Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...The new research reports from Market Source Research, available for free download at the links above, examine Arcus Biosciences, Inc. (NYSE:RCUS), Ion Geophysical Corporation (NYSE:IO), A.H. Belo ...Arcus Biosciences, Inc. (NYSE:RCUS) shares were also up, gaining 25% to $21.83. Citigroup maintained Arcus Biosciences with a Buy. Equities Trading DOWN.HAYWARD, Calif., February 09, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...NYSE Composite Today: Get all information on the NYSE Composite Index including historical chart, news and constituents. Indices Commodities Currencies StocksArcus Biosciences press release (NYSE:RCUS): Q3 GAAP EPS of -$0.94 beats by $0.19. Revenue of $32M (-3.0% Y/Y) beats by $4.44M. $950 million in cash, cash equivalents and marketable securities and ...Each major bond market around the world has its own closing hours, but the New York Stock Exchange (NYSE) closes at 4:30 p.m. EST, according to the Financial Web. Bond trading begins on the NYSE at 9:30 a.m. EST.Arcus Biosciences ( NYSE:RCUS – Get Free Report) last announced its earnings results on Tuesday, November 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating ...Arcus Biosciences Inc stock price (RCUS) NYSE: RCUS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert …HAYWARD, Calif.--(BUSINESS WIRE)--Arcus BioscienFOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS May 17, 2023 · HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ... HAYWARD, Calif., October 17, 2023--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ... Experience · Spotify officially begins tr 13 hours ago · Exelixis, Inc. (Nasdaq: EXEL) and Arcus Biosciences (NYSE: RCUS) today announced that the companies have entered into a clinical trial collaboration f Nov 7, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules ... 8 ngày trước ... RCUS #ManagementChanges #NYSE #New

Shares of Arcus Biosciences ( RCUS 3.94%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT ...FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth ...HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS) today announced that data from cohort A1 of the ongoing Phase 2 EDGE-Gastric study will be presented at the American Society ...RCUS Earnings Date and Information. Arcus Biosciences last announced its earnings data on November 7th, 2023. The reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.18. The business earned $32 million during the quarter, compared to analyst estimates of $27.57 million. …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Gilead Sciences (NASDAQ:GILD) inks a 10-ye. Possible cause: HAYWARD, Calif., November 13, 2023--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-.